Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Journal of Acquired Immune Deficiency Syndromes - JAIDS Année : 2012

Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.

Résumé

Among 103 patients with multidrug-resistant HIV who initiated raltegravir, etravirine, and darunavir/ritonavir-containing regimen in the ANRS 139 TRIO trial, 100 participated in extended follow-up and continued study treatment until week 96. Among them, 87 (87%) received an optimized background therapy including either nucleoside reverse transcriptase inhibitors or enfuvirtide, they were 78 (78%) at week 96. At week 96, 88% achieved durable virologic response (<50 copies/mL). CD4 response was maintained (median change of +150 cells/mm(3)). No major toxicity was reported. This triple drug combination showed sustained efficacy and thus should be strongly considered for patients with multiclass-resistant virus.

Domaines

Immunologie

Dates et versions

hal-00875207 , version 1 (21-10-2013)

Identifiants

Citer

Catherine Fagard, Céline Colin, Charlotte Charpentier, Agathe Rami, Christine Jacomet, et al.. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.. Journal of Acquired Immune Deficiency Syndromes - JAIDS, 2012, 59 (5), pp.489-93. ⟨10.1097/QAI.0b013e31824bb720⟩. ⟨hal-00875207⟩
151 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More